Study Title: Phase I/II Multisite, Randomized, Controlled Study of Monoclonal Antibody VRC01 with Combination Antiretroviral Therapy to Promote Clearance of HIV-1-Infected Cells in Infants
IMPAACT 2008 is a Phase I/II, multisite, randomized controlled study of monoclonal antibody VRC01 combined with antiretroviral therapy in infants. The study is designed to assess the safety of VRC01 administered with ART (through Week 14) and the effect of VRC01 on HIV-1 DNA concentrations in peripheral blood (at Week 14) among HIV-1-infected infants. The study is closed to follow-up.
Location: HFC CRS